Multiple Myeloma and Plasma Cell Neoplasm
295
3
4
209
Key Insights
Highlights
Success Rate
81% trial completion
Published Results
61 trials with published results (21%)
Research Maturity
209 completed trials (71% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
16.3%
48 terminated out of 295 trials
81.3%
-5.2% vs benchmark
13%
38 trials in Phase 3/4
29%
61 of 209 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 209 completed trials
Clinical Trials (295)
A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Registry of Older Patients With Cancer
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma
Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis
Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation
Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma
Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma
Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma
Collecting and Storing Blood Samples From Patients With Cancer
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant